|
注册号: Registration number: |
ChiCTR2600125052 |
|
最近更新日期: Date of Last Refreshed on: |
2026-05-20 17:05:20 |
|
注册时间: Date of Registration: |
2026-05-20 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
直接抗病毒药物治疗基因 1 型慢性丙型肝炎的疗效、安全性和药物经济学 评价:一项多中心真实世界研究 |
|
Public title: |
Evaluation of the Efficacy, Safety, and Pharmacoeconomic Impact of Direct Antiviral Therapy for Genotype 1 Chronic Hepatitis C: A Multicenter Real-World Study. |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
直接抗病毒药物治疗基因 1 型慢性丙型肝炎的疗效、安全性和药物经济学 评价:一项多中心真实世界研究 |
|
Scientific title: |
Evaluation of the Efficacy, Safety, and Pharmacoeconomic Impact of Direct Antiviral Therapy for Genotype 1 Chronic Hepatitis C: A Multicenter Real-World Study. |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
廖娟 |
研究负责人: |
白浪 |
|
Applicant: |
Juan Liao |
Study leader: |
Lang Bai |
|
申请注册联系人电话: Applicant telephone: |
+86 28 8542 4838 |
研究负责人电话:
Study leader's |
+86 28 8542 4838 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
hxcrgcp@163.com |
研究负责人电子邮件: Study leader's E-mail: |
pangbailang@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省成都市武侯区国学巷37号 |
研究负责人通讯地址: |
四川省成都市武侯区国学巷37号 |
|
Applicant address: |
No. 37, Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province |
Study leader's address: |
No. 37, Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital of Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital of Sichuan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2026年审(371)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院生物医学伦理审查委员会 |
||
|
Name of the ethic committee: |
Biomedical Ethics Review Committee of West China Hospital of Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-03-24 00:00:00 | ||
|
伦理委员会联系人: |
李娜 |
||
|
Contact Name of the ethic committee: |
Na Li |
||
|
伦理委员会联系地址: |
四川省成都市武侯区国学巷37号 |
||
|
Contact Address of the ethic committee: |
No. 37, Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 8542 2654 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital of Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市武侯区国学巷37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 37, Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
四川省医学科技转化发展基金会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Sichuan Medical Science and Technology Transformation and Development Foundation |
||||||||||||||||||||||
|
研究疾病: |
慢性丙型病毒性肝炎 |
||||||||||||||||||||||
|
Target disease: |
chronic hepatitis C |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
1.比较分析磷酸依米他韦/索磷布韦、索磷布韦维帕他韦、盐酸可洛派韦/索磷布韦在基因1型慢性丙肝患者治疗结束后12周时的持续病毒学应答率(SVR12); 2.安全性评估:包括不良事件、严重不良事件、不良反应、与药物相关严重不良事件发生率等; 3.以 SVR12为效果指标,以直接医疗成本为成本指标,计算成本-效果比和增量成本-效果比,比较三种方案的经济学价值 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Compare and analyze the sustained virologic response at 12 weeks post-treatment (SVR12) of phosphoric acid imitativer/Sofosbuvir, Sofosbuvir/Velpatasvir, and hydrochloride coropavir/Sofosbuvir in patients with genotype 1 chronic hepatitis C; 2. Safety assessment: including adverse events, serious adverse events, adverse reactions, incidence of drug-related serious adverse events, etc.; 3. Using SVR12 as the effectiveness indicator and direct medical costs as the cost indicator, calculate the cost-effectiveness ratio and incremental cost-effectiveness ratio, and compare the economic value of the three regimens. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.缺乏基本的人口统计学和临床特征; 2.非基因1型者; 3.三个月内参加HCV治疗的其他药物临床试验; 4.数据缺失且不满足基本统计分析需求; 5.既往接受过直接抗病毒治疗者 6.研究者认为不适宜参加者 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Lack of basic demographic and clinical characteristics; 2. Non-genotype 1 individuals; 3. Participation in other drug clinical trials for HCV treatment within three months; 4. Missing data and not meeting basic statistical analysis requirements; 5. Previously received direct antiviral treatment; 6. Participants deemed unsuitable by the investigator |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-05-20 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-05-20 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
http://www.medresman.org.cn/login.aspx |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
http://www.medresman.org.cn/login.aspx |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |